Zulresso is also the first drug developed by and approved from Sage Therapeutics, a Cambridge, Mass.-based biotech.
Postpartum depression disorder, which affects approximately 400,000 women each year, is a major depressive episode that occurs following childbirth.
Zulresso, also known as brexanolone, is designed to work faster than other antidepressants and is administered intravenously.
Sage told The Wall Street Journal that it will cost $7,450 per vial, or $34,000 for an average course of therapy, before any discounts.
The drug will also need to be administered in a hospital or clinic.
More articles on pharmacy:
Harvard gets $100M infusion for drug research from hedge fund
Purdue Pharma CEO: Bankruptcy is ‘an option’ amid lawsuits
Intermountain CEO Dr. Marc Harrison: How Civica Rx will disrupt the drug industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
